特发性肺纤维化药物治疗推荐

Recommendations for drug treatment of idiopathic pulmonary fibrosis

摘要:

特发性肺纤维化(IPF)是一种原因不明的纤维化性间质性肺炎,生存率及预后极差,临床上IPF治疗药物十分有限。2011年美国胸科学会、欧洲呼吸学会、日本呼吸学会和拉丁美洲胸科学会共同发表的《IPF诊治循证指南》为IPF药物治疗提供了建议。但随后的一些临床试验结果与2011年指南中治疗推荐相矛盾。2015年该机构又发表了一个补充指南。本文对2011年以来指南中治疗IPF的药物进行了回顾,同时综述了2015年补充指南对各药物的推荐情况。

Abstract:

Idiopathic pulmonary fibrosis (IPF) is an idiopathic interstitial pneumonia with poor survival and poor prognosis. But, there are very limited clinical treatments for the disease. In 2011, the American Thoracic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory Society (JRS) and the Latin American Thoracic Society (ALAT) published idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management, and provided treatment proposals. But afterwards, the results of some clinical trials were in conflict with the recommendations in the 2011 guideline. In 2015, the agency issued an update of the 2011 clinical practice guideline. In this paper, we reviewed the drugs for the treatment of IPF in the guidelines in 2011, and the recommendations for each drug in the 2015 update.